Shanghai Yidan Biotechnology

Shanghai Yidan Biotechnology is an innovative biopharmaceutical company focused on the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design bifunctional molecules, such as PROTACs and molecular glues, aimed at addressing previously undruggable targets in oncology and autoimmune diseases. Their current research efforts are primarily directed toward hormone-driven cancers, including prostate and breast cancer, as well as hematological malignancies. By optimizing the degradation of pathogenic proteins, Yidan Biotech seeks to overcome resistance mechanisms associated with traditional small molecule inhibitors. The company is headquartered in Shanghai's high-tech medical hubs and is actively advancing its lead candidates through the pre-clinical pipeline.